Lumida
/SMMT
⌘K
Summit Therapeutics Inc

Summit Therapeutics Inc

SMMT
$17.55USD+3.24%+0.55 today

MARKET CAP

14.0B

P/E (TTM)

FWD P/E

DAY RANGE

$17 – $18

52W RANGE

$12
$29

AI Summary

Stalk
StalkMedium

SMMT has triggered a clear momentum breakout and exhibits bullish medium-term structure supported by active continuation patterns. However, price is extended above rising EMAs with extreme overbought readings, warranting patience. A deferred buy on pullbacks into the rising 9/20 EMA zone aligns with speculative strategy discipline and manages risk against the longer-term downtrend.

  • Ibanesimab delivered statistically significant PFS in four Phase III trials.
  • $690.7M cash balance and zero debt fund PDUFA readiness.
  • Approval uncertain without statistically significant overall survival benefit.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2019FY 2020FY 2021FY 2022TREND
Sales, Adj.$57.1M$860,000$1.8M$705,000
YoY %-98.5%+110.3%-61.0%
P / Sales0.4x380.0x195.9x1371.2x
EV / Sales0.4x329.5x172.8x1639.1x
Gross Profit, Adj.$57.1M$860,000$1.8M$705,000
YoY %-98.5%+110.3%-61.0%
Margin %100.0%100.0%100.0%100.0%
EV / Gross Profit0.4x329.5x172.8x1639.1x
EBITDA, Adj.$12.6M$-50.3M$-83.7M$-62.4M
YoY %+142.6%-498.5%-66.4%+25.5%
Margin %22.1%-5852.4%-4628.6%-8845.1%
EV / EBITDA1.8x-5.6x-3.7x-18.5x
EBIT$5.4M$-53.2M$-86.2M$-72.1M
YoY %+118.1%-1087.1%-62.0%+16.4%
Margin %9.4%-6185.2%-4764.3%-10225.4%
EV / EBIT4.3x-5.3x-3.6x-16.0x
Net Income$10.9M$-52.7M$-88.6M$-78.8M
YoY %+137.0%-584.8%-68.1%+11.1%
Net Margin19.0%-6127.6%-4897.8%-11174.8%
EPS (GAAP)$0.63-$0.76-$0.67-$0.41
YoY %+226.0%-220.6%+11.8%+38.8%